Drug Trial Radar · NCT05946941
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome
Last checked: Nov 19, 2026Latest source record: Apr 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
774
Actual
Start
Sep 11, 2023
Primary completion
Nov 18, 2026
Study completion Nov 16, 2028
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jul 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and efficacy of two doses of Deucravacitinib in adult participants with Active Sjögren's Syndrome.
Conditions
- Sjögren's Syndrome
Interventions
DeucravacitinibDrug
Specified dose on specified days
PlaceboOther
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI) Score at Week 52Time frame: Baseline, Week 52
Locations
199 sites in 33 countries. Site status is shown where the registry gives one.
Local Institution - 0228
Fullerton, California
Local Institution - 0222
La Palma, California
Local Institution - 0218
San Francisco, California
Local Institution - 0203
Santa Monica, California
Local Institution - 0067
Denver, Colorado
Local Institution - 0049
Clearwater, Florida
Local Institution - 0226
Cooper City, Florida
Local Institution - 0223
Sarasota, Florida
Local Institution - 0140
Augusta, Georgia
Local Institution - 0229
Lawrenceville, Georgia
Local Institution - 0174
Skokie, Illinois
Local Institution - 0016
Kansas City, Kansas
Local Institution - 0017
Baton Rouge, Louisiana
Local Institution - 0125
Monroe, Louisiana
Local Institution - 0187
Baltimore, Maryland
Local Institution - 0173
Boston, Massachusetts
Local Institution - 0131
Eagan, Minnesota
Local Institution - 0138
Summit, New Jersey
Local Institution - 0009
Albuquerque, New Mexico
Local Institution - 0184
Mineola, New York
Local Institution - 0224
Salisbury, North Carolina
Local Institution - 0130
Duncansville, Pennsylvania
Local Institution - 0022
Jackson, Tennessee
Local Institution - 0144
Allen, Texas
Local Institution - 0227
Katy, Texas
Local Institution - 0175
Plano, Texas
Local Institution - 0133
Seattle, Washington
Local Institution - 0189
Spokane, Washington
Local Institution - 0137
CABA, Argentina
Local Institution - 0109
City of Buenos Aires, Argentina
Local Institution - 0061
Córdoba, Argentina
Local Institution - 0050
San Isidro, Alabama, Argentina
Local Institution - 0100
CABA, Buenos Aires, Argentina
Local Institution - 0003
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Local Institution - 0019
Quilmes, Buenos Aires, Argentina
Local Institution - 0026
San Miguel de Tucumán, Tucumán Province, Argentina
Local Institution - 0120
Woodville South, South Australia, Australia
Local Institution - 0117
Graz, Austria
Local Institution - 0087
Vienna, Austria
Local Institution - 0172
Ghent, Belgium
Showing 40 of 199 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.